| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1bbad2c2687218e6437629b70623223 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-421
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 |
| filingDate |
2014-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7dbc619d3898bbecfa4910d5954fc2f |
| publicationDate |
2020-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MY-181226-A |
| titleOfInvention |
Formulation of metaxalone |
| abstract |
Dosage forms of metaxalone containing submicron particles of metaxalone and uses thereof are described. The submicron dosage forms have improved bioavailability compared to certain conventional metaxalone dosage forms. Figure 1 |
| priorityDate |
2013-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |